Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase

Despite the remarkable success of imatinib against Bcr-Abl, development of secondary resistance, most often due to point mutations in the Bcr-Abl tyrosine kinase (TK) domain, is quite common. Of these, the T315I “gatekeeper” mutation is resistant to all currently registered Bcr-Abl TK inhibitors (TK...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bose, Prithviraj, Park, Haeseong, Al-Khafaji, Jawad, Grant, Steven
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2013
Assuntos:
Brief Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3747003/
https://ncbi.nlm.nih.gov/pubmed/23977454
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2013.02.001
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados